Seminal Soluble Urokinase Plasminogen Activator (suPAR) Is a Marker of Male Accessory Gland Inflammation

Presentation Number: THR-135
Date of Presentation: March 5th, 2015

Giuseppe Grande*1, Domenico Milardi1, Silvia Baroni2, Chiara Autilio2, Renato Morelli2, Cecilia Zuppi2, Laura De Marinis3, Riccardo Marana2 and Alfredo Pontecorvi2
1Catholic University of the Sacred Heart, Rome, Italy, 2Catholic University, Rome, Italy, 3Università Cattolica del Sacro Cuore, Rome, Italy


The association between MAGI (Male Accessory Gland Infection) and infertility is a major andrological debate (1). Standard semen analysis, leukocytospermia and microbiological tests are not often enough for the diagnosis. A large amount of biochemical parameters in seminal plasma have been suggested as inflammation markers, nevertheless there is not yet a sensitive and specific  biomarker that accurately identify MAGI (2).

We investigated in semen the presence of suPAR (soluble urokinase-type Plasminogen Activator Receptor), known marker of systemic inflammation (3), to evaluate its possible involvement in urogenital tract inflammation.

On the basis of andrological evaluation, including spermiogram and ultrasound signs of MAGI, we selected 76 patients with MAGI and 30 healthy men as control group. Patients were  classified according to semen culture in group A (n=28) with bacterial MAGI and group B (n=48) with abacterial MAGI. C-reactive protein (CRP), total protein (TP), procalcitonin (PCT), leucocytes peroxidase (LP) and suPAR concentrations were assayed on seminal plasma.

 Spermiogram parameters were significantly lower in patients than in controls. CRP, TP, PCT and LP were not different in all subjects. suPAR was detectable in all semen samples; it was significantly increased in A and B groups (median: 78.5 vs 41.0 ng/ml in controls) and inversely correlated to sperm parameters. We selected by ROC curve a suPAR cut-off value of 55.3 ng/ml as diagnostic threshold to detect MAGI.

We report the first evidence of suPAR presence in seminal plasma, focusing on its interesting role as reliable, sensitive and specific marker of inflammation in differential diagnosis of MAGI.


Disclosure: LD: Principal Investigator, Novartis Pharmaceuticals, Consultant, Ipsen, Speaker, Lilly USA, LLC. Nothing to Disclose: GG, DM, SB, CA, RM, CZ, RM, AP